Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to compare the effects of the addition of tamoxifen to epirubicin versus epirubicin alone on VEGF and VEGFR2 expression in breast cancer patients. The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment. Epirubicin alone failed to induce changes in VEGF expression (P = 0.54), while the addition of tamoxifen to epirubicin resulted in a significant reduction in VEGF expression (P < 0.001). As a consequence, baseline VEGF had a negative prognostic role in patients who received epirubicin alone but not in patients receiving epirubicin plus tamoxifen (interaction test P < 0.05). VEGFR2 expression increased at residual tumor histology in both treatment arms, with a lesser extent in patients receiving tamoxifen plus epirubicin. Decrease in VEGFR2 expression was significantly associated with response rate (P = 0.02). The addition of tamoxifen to epirubicin resulted in a suppression of a key angiogenic pathway. These data suggest a potential synergism of these two drugs.

Original publication

DOI

10.1007/s10549-010-1063-0

Type

Journal article

Journal

Breast cancer res treat

Publication Date

10/2010

Volume

123

Pages

795 - 804

Keywords

Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chi-Square Distribution, Disease-Free Survival, Drug Synergism, Epirubicin, Female, Humans, Immunohistochemistry, Italy, Kaplan-Meier Estimate, Neoplasm Staging, Neovascularization, Pathologic, Proportional Hazards Models, Prospective Studies, Risk Assessment, Risk Factors, Tamoxifen, Time Factors, Tissue Array Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2